We are pleased to announce a new collaboration with Incyte utilizing #AI to unlock the discovery of breakthrough small molecule medicines.? We are combining our proprietary GEMS AI platform with Incyte’s longstanding expertise in drug development with the goal of creating novel treatments for patients in need. Genesis and Incyte will collaborate on two initial targets, and Genesis will receive an upfront payment of $30 million. Genesis is also eligible for up to $295 million in development, regulatory and commercial milestone payments per target. Learn more at https://lnkd.in/gvqRXvhj
Genesis Therapeutics
生物技术研究
Burlingame，California 14,743 位关注者
Unifying AI and Biotech to accelerate the discovery of new medicines
关于我们
Genesis Therapeutics – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego – is unifying AI and biotechnology to discover novel and breakthrough treatments for patients with severe and devastating conditions. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery. The GEMS platform integrates deep learning-based predictive models, molecular simulations, and molecular generative AI. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through multiple cycles of AI-enabled discovery and optimization. We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022) and Genentech (signed in 2020). Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. We are rapidly growing our team with a variety of openings on our machine learning, computational chemistry, and software teams (primarily located in the Bay Area) and our chemistry, biology, and clinical teams (primarily located in San Diego). To learn more about Genesis Therapeutics, or current employment opportunities, please visit our website.
- 网站
-
https://www.genesistherapeutics.ai
Genesis Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Burlingame，California
- 类型
- 私人持股
- 领域
- Deep Learning、Drug Discovery、Artificial Intelligence和Drug Development
地点
Genesis Therapeutics员工
动态
-
Great to see Genesis highlighted in our board member Vijay Pande, PhD’s recent interview with Alex Philippidis in Genetic Engineering & Biotechnology News. Check out the article for their discussion on the impact of #AI in the biopharma industry and how this technology is transforming the future of healthcare. https://lnkd.in/gW9et2gQ
-
Our thanks to Mike May for spotlighting our CEO Evan Feinberg in Genetic Engineering & Biotechnology News’ "AI Accelerates and Expands Drug Development" featured article. As Evan mentions, from its very inception, Genesis has been “devoted to the development of novel, differentiated AI specifically for the purpose of drug discovery.” https://lnkd.in/guK3VCMh #AI #DrugDiscovery #GenAI #Biotech
-
Happy Holidays from the Genesis team! ?? As 2024 comes to a close, we’re reflecting on a year of incredible progress—announcing collaborations with Gilead Sciences and NVIDIA, partnering with the Massachusetts Institute of Technology team on the Boltz-1 model, expanding our talented team, and all the while continuously advancing our GEMS platform to push the boundaries of AI-driven small molecule drug discovery. We’re incredibly grateful for the support of our team, partners, and investors. Here’s to even more progress in 2025! #AI #DrugDiscovery #GenAI #Biotech
-
“There’s a lot of very clear synergies between Nvidia’s comparative advantages and Genesis’s comparative advantages that make the combination more than the sum of the parts.” CEO Evan Feinberg recently shared with Alex Philippidis the significance of our collaboration with NVIDIA and what it means for the future of AI-powered drug discovery. Read the full piece in Genetic Engineering & Biotechnology News? ?? https://lnkd.in/g7XXBUYW? #AI #DrugDiscovery #GenAI #Biotech
-
We’re thrilled to welcome Shifeng Pan, Alla Ivanova, and Dr. Paul Friedman to our senior leadership team! ?? Shifeng Pan joined in April as our Chief Scientific Officer, leading R&D for our pipeline of AI-enabled therapeutics. He brings over two decades of experience in medicinal chemistry and biopharmaceutical research, and contributed to the discovery of numerous FDA-approved drugs at Novartis/GNF. ?? Alla Ivanova joined the team last month as our Senior Vice President of Engineering, bringing 25+ years of expertise driving AI and software innovations at Google, Uber, Netflix, and more. ?? Dr. Paul Friedman has served as Chairman of our Board of Directors since April. As a veteran biotech leader, he brings invaluable expertise from Incyte, Madrigal Pharmaceuticals, and Merck. Learn more about today’s announcement ??https://lnkd.in/gFDqNYEK Interested in joining our team? Explore our open roles ?? https://lnkd.in/ggmRNRzP #AI #DrugDiscovery #GenAI #Biotech #Hiring
-
We’re thrilled to welcome Michael V. LeVine to the Genesis team! Michael joins us as Director of Computational Biophysics, leading our computational chemistry and computational drug discovery efforts. As a theoretical biophysicist, computational chemist, and drug discovery scientist, he brings over a decade of experience to our team after leading groups at research and academic institutions including D. E. Shaw Research and Weill Cornell Medicine. We couldn’t be more excited to have Michael on board as we continue combining AI and physics to revolutionize small-molecule drug discovery. Interested in joining us? Check out our open roles ?? https://lnkd.in/ggmRNRzP #AI #DrugDiscovery #GenAI #Biotech #Hiring
-
-
Attending #NeurIPS2024 next week? Be sure to stop by booth #59 at the expo to meet our Genesis Research team and learn more about our recent progress, what it’s like to work at Genesis, and more! Also, our research scientist, Gianluca Scarpellini will be presenting a poster at the conference. Be sure to stop by and learn how he is applying his background in computer vision and reinforcement learning to create generative models for biotech applications - details below. Date & Time: Dec. 13 from 4:30-7:30 pm PT? Location: West Ballroom A-D #5210 Title: Re-assembling the past: The RePAIR dataset and benchmark for real world 2D and 3D puzzle solving #MachineLearning #GenerativeAI #DiffusionModels #GenesisResearch #AIDrugDiscovery
-
-
Our CEO Evan Feinberg shared with STAT’s Brittany Trang how our AI platform, GEMS, works as a supercharged search engine for small molecule drug discovery. By transforming how we explore molecular space, GEMS is enabling breakthroughs in drug discovery and bringing new hope to patients with severe diseases. Learn more about how we're driving innovation in AI + physics for small molecule drug discovery ?? https://lnkd.in/gw6p463Y
-
In a few weeks, our Genesis Research team will be heading to Vancouver for #NeurIPS2024 ???? If you’ll be attending and would like to learn more about us, our recent collaboration with NVIDIA, work with the Massachusetts Institute of Technology team on the Boltz-1 model, or what it’s like to work at Genesis, stop by booth #59 at the expo. Interested in learning more about our open roles ahead of time? Visit ?? https://lnkd.in/gjJQCYJk ?#MachineLearning #GenerativeAI #DiffusionModels #GenesisResearch #AIDrugDiscovery
-